Skip to main content

ResMed Welcomes Urvashi Tyagi as New Chief Technology Officer

Urvashi Tyagi, ResMed Chief Technology Officer

Urvashi Tyagi, ResMed Chief Technology Officer

Urvashi Tyagi, ResMed Chief Technology Officer

  • Tyagi brings over 25 years’ IT and leadership experience from ADP, American Express, Amazon, Microsoft, and IBM
  • Current CTO and SaaS President Bobby Ghoshal now transitions to SaaS full-time

SAN DIEGO, Feb. 01, 2022 (GLOBE NEWSWIRE) — ResMed (NYSE: RMD, ASX: RMD) today announced the appointment of Urvashi Tyagi as chief technology officer (CTO), effective today.

As CTO, Tyagi will lead ResMed’s Digital Health Technology team, driving the innovation and adoption of its world-leading cloud-based digital health platforms, as well as investments in emerging technologies like artificial intelligence and machine learning.

Tyagi has over 25 years’ experience in IT and mechanical engineering, user experience, finance, business development, and executive leadership. Before joining ResMed, she was chief technology officer and senior vice president for ADP. She was previously global head of commercial data engineering for American Express, and before that held senior roles at Amazon’s Audible business, Microsoft, and IBM.

“Urvashi brings world-class technology and engineering know-how, combined with senior leadership experience from other top fintech and consumer tech companies, that will help ResMed accelerate growth of our digital ecosystem, and achieve our goal of improving the lives of 250 million people in 2025,” said ResMed CEO Mick Farrell. “Urvashi has seen and developed best practices in technology across multiple industries, and her strong leadership and team development skills will help her infuse those learnings and practices into the market-transforming work we do here at ResMed.”

With Tyagi’s hire, previous CTO and current SaaS President Bobby Ghoshal now transitions full-time into leading ResMed’s SaaS business, which provides software solutions that enable thousands of out-of-hospital care agencies to work more efficiently to deliver personalized care.

“Bobby has done a tremendous job as ResMed’s first CTO, starting in that role in 2018,” Farrell said. “I’d like to thank Bobby for helping strengthen our Digital Health Technology team with world-class talent and leadership, and I am excited that he can now be laser focused on accelerating growth in our SaaS business, building on the work he did as the COO for Brightree in 2016. ResMed’s leadership in software as a service provides market-leading solutions for healthcare providers, whole healthcare systems, and most important, the tens of millions of patients, residents, and seniors who rely on out-of-hospital care every day.”

About ResMed
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.

For media
Jayme Rubenstein
+1 858.836.6798
news@resmed.com
                 For investors
Amy Wakeham
+1 858.836.5000
investorrelations@resmed.com
   

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7f8c8bcd-cc85-4a41-8f68-a9e77c74f7f5

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.